| Bioactivity | HBV-IN-21 (Compound II-8b) is an HBV DNA replication inhibitor with an IC50 of 2.2 µM. HBV-IN-21 can interact HBV 4 capsid protein with good affinity (KD = 60.0 μM)[1]. |
| Target | IC50: 2.2 µM (HBV DNA replication) |
| Name | HBV-IN-21 |
| CAS | 2460957-52-0 |
| Formula | C17H17FN4OS2 |
| Molar Mass | 376.47 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Jia H, et al. Design, diversity-oriented synthesis and biological evaluation of novel heterocycle derivatives as non-nucleoside HBV capsid protein inhibitors. Eur J Med Chem. 2020 Sep 15;202:112495. |
HBV-IN-21
CAS: 2460957-52-0 F: C17H17FN4OS2 W: 376.47
HBV-IN-21 (Compound II-8b) is an HBV DNA replication inhibitor with an IC50 of 2.2 µM. HBV-IN-21 can interact HBV 4 cap
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.